Gastrointestinal prostheses having partial bypass configurations

Information

  • Patent Grant
  • 8702641
  • Patent Number
    8,702,641
  • Date Filed
    Friday, January 7, 2011
    14 years ago
  • Date Issued
    Tuesday, April 22, 2014
    10 years ago
Abstract
A system of components may be used separately or in combination to create partial bypass of food, stomach and intestinal secretions and digestive enzymes. The systems are designed to be modular so as to allow the physicians to quickly replace certain elements to tailor the amount of material bypassed, the restriction applied to food passage, and the origin and destination of bypass according to the patient's individualized clinical needs.
Description
TECHNICAL FIELD

This invention generally relates to implants placed within gastrointestinal systems, including the esophagus, the stomach, and the intestines. In particular, it relates to implant systems having components implantable and removable using laparoscopic and endoscopic techniques for treatment of obesity, diabetes, reflux, and other gastrointestinal conditions.


BACKGROUND

Bariatric surgery procedures, such as sleeve gastrectomy, the Rouen-Y gastric bypass (RYGB), and the biliopancreatic diversion (BPD), modify food intake and/or absorption within the gastrointestinal system to effect weight loss in obese patients. These procedures affect metabolic processes within the gastrointestinal system, by either short-circuiting certain natural pathways or creating different interaction between the consumed food, the digestive tract, its secretions and the neuro-hormonal system regulating food intake and metabolism. In recent years, there has been a growing clinical consensus that obese diabetic patients who undergo bariatric surgery see remarkable resolution of their Type-2 Diabetes Mellitus (T2DM) soon after the procedure. The remarkable resolution of diabetes after RYGB and BPD typically occurs too fast to be accounted for by weight loss alone, suggesting that there may be a direct impact on glucose homeostasis. The mechanism of this resolution of T2DM is not well understood, and it is quite likely that multiple mechanisms are involved.


One of the drawbacks of bariatric surgical procedures is that they require fairly invasive surgery with potentially serious complications and long patient recovery periods. In recent years, there is an increasing amount of ongoing effort to develop minimally invasive procedures to mimic the effects of bariatric surgery using minimally invasive procedures. One such procedure involves the use of gastrointestinal implants that modify transport and absorption of food and organ secretions. For example, U.S. Pat. No. 7,476,256 describes an implant having a tubular sleeve with an anchor having barbs. While these implants may be delivered endoscopically, the implants offer the physician limited flexibility and are not readily removable or replaceable, as the entire implant is subject to tissue in-growth after implantation. Moreover, stents with active fixation means, such as barbs that penetrate into the surrounding tissue, may potentially cause tissue necrosis and erosion of the implants through the tissue, which can lead to serious complications such as systemic infection. Also, due to the intermittent peristaltic motion within the digestive tract, implants such as stents have a tendency to migrate.


SUMMARY

According to various embodiments, the present invention is a partial gastrointestinal implant system for treating metabolic disorders, such as diabetes and obesity. According to some embodiments, the system includes an anchoring element (e.g., stents, rings, fabric, or elastomeric cuffs) with sleeve or graft extensions, anchored within the gastrointestinal system (e.g., the esophagus, the gastro-esophageal junction, the pyloric junction, the duodenum, the jejunum, and/or the ileum), the anchoring element including docking capability, and tubular implants (e.g., thin sleeves or stent grafts) configured to be reversibly attached to the anchoring element. According to some embodiments, the system allows attachment of one or multiple tubular implants to the gastrointestinal anchoring element. According to some embodiments, the cross-section area of the implants can be varied or adjusted, such that systems can be created where food or secretions entering the proximal portion of the system can be selectively channeled to alternate destinations, thereby creating customized and partial bypass systems. By adjusting the sizing of the sleeves and the restrictive elements in the system, this procedure can also simulate mechanisms of restrictive surgical procedures.


According to various embodiments, the present invention is a modular intra-luminal implant system for treating metabolic disorders such as obesity and diabetes, which provides far more flexible therapy alternatives than single devices to treat these disorders. These implant systems include components that can be selectively added or removed to mimic a variety of bariatric surgical procedures with a single basic construct. The fundamental building blocks of the system include anchoring implants that are placed within the GI system or some instances around particular organs. These low-profile implants are designed for long-term performance with minimal interference with normal physiological processes. Features of these anchoring implants allow them to act as docking stations for therapy implants designed for achieving certain metabolic modification goals. By using a combination of anchoring implants with corresponding replaceable tubular elements that dock with them, it is possible to design therapies with particular metabolic modification goals or those that mimic currently practiced bariatric surgical procedures. This allows the physician to customize the therapy to the patient at the time of the initial procedure but also allows the flexibility to alter the therapy during the lifetime of the patient by replacing individual components.


According to some embodiments, the modular systems of the invention includes an anchoring implant portion (docking element) including an expandable structure (e.g., a low profile stent or ring or fabric/elastomeric cuff) anchored within the esophagus, the gastro-esophageal junction, the pyloric junction, the duodenum or the jejunum and may have sleeve or graft extensions. The stents may be balloon expandable or self-expanding and anchor against the tissue with radial force. The rings could be made of self-expanding nitinol and anchor to the tissue by entrapment of the tissue within the ring elements or by radial force. The cuffs could be either sutured or stapled or permanently or reversibly attached by other mechanical means to the tissue. The anchoring implant includes or is adapted to receive (e.g., endoscopically) features that enable docking functionality. The docking functionality of the stent, ring or cuff, for example, could take the form of magnetic elements, hooks, mating mechanical elements or structures (e.g., the stent braid or mesh or corresponding hook and loop structures) that are integral to the framework of the stent, ring or cuff or the sleeve or graft extension. The system also could be such that the docking functionality is not integral to the stent, ring or cuff but is introduced later by attaching other elements such as magnets, hooks, mating mechanical elements, etc. to the framework of the stent, ring, cuff or to the sleeve/graft extension of the above implants. Therapeutic implants, such as tubular sleeves or stent grafts, are adapted to be reversibly attached to the anchoring implants. These therapeutic implants will have corresponding features (e.g., magnets, hooks, mechanical elements) to enable docking to the anchoring implants, so that the therapeutic implants can be reversibly attached to the anchoring implants. In some embodiments, the tubular implants will not be in contact with tissue to minimize or prevent tissue in-growth and facilitate easy removal with endoscopic instrumentation after long-term implantation.


The present invention, according to various embodiments, includes a modular gastrointestinal implant system for treating metabolic disorders such as diabetes and obesity by creating partial internal bypasses of food and organ secretions within the gastro-intestinal tract. The system includes low-profile anchoring implants that are affixed within the stomach, the esophagus, the intestine (or at internal junctions of these organs) or around these organs and enable secure attachment of (i.e., act as docking elements for) other implants; and other implants whose design facilitates partial internal by-pass of food and organ secretions from one site within the gastro-intestinal tract to other sites within the gastro-intestinal tract (partial bypass elements) that are attached to these anchoring implants. In some embodiments, the low-profile implant is a stent-graft or a stent with a sleeve element. In some embodiments, the low-profile implant is a fabric or elastomeric cuff. In some embodiments, the low-profile implants are stents divided into multiple channels. In some embodiments, the low-profile implants are multi-limb stent-grafts.


According to various embodiments, the present invention is a method for treating metabolic disorders such as diabetes and obesity consisting of (a) placing low-profile implants that can be affixed within the stomach, the esophagus, the intestine or at internal junctions of these organs or around these organs and (b) securely attaching other gastro-intestinal implants that permit partial internal by-pass of food and organ secretions from one site within the gastro-intestinal tract to other sites within the gastro-intestinal tract, to these low-profile implants.


According to various embodiments, the present invention is a method for creating a reversible treatment for metabolic disorders such as diabetes and obesity consisting of (a) placing low-profile implants that can be affixed within the stomach, the esophagus, the intestine or at internal junctions of these organs or around these organs and (b) placing other gastro-intestinal implants that permit partial internal by-pass of food and organ secretions from one site within the gastro-intestinal tract to other sites within the gastro-intestinal tract, to these low-profile implants and not to the tissue so that the procedure can be reversed easily.


According to various embodiments, the present invention is a modular system for selectively restricting passage of food and organ secretions within the gastro-intestinal tract that consists of (a) low-profile implants that are affixed within the stomach, the esophagus, the intestine or at internal junctions of these organs or around these organs and which enable secure attachment of other implants (docking elements) and (b) other gastro-intestinal implants whose design facilitates selective restriction of passage of food and organ secretions from one site within the gastro-intestinal tract to other sites within the gastro-intestinal tract that are attached to these permanent implants (restrictive bypass elements). In some embodiments, the structure or design feature of the implant that enables secure attachment of one or more implants to it consists of a double-braid with hollow space between the two braids.


According to various embodiments, the present invention is a method for treating metabolic disorders such as diabetes and consisting of (a) placing low-profile implants that can be affixed within the stomach, the esophagus, the intestine or at internal junctions of these organs or around these organs and (b) securely attaching other gastro-intestinal implants that selectively restrict passage of food and organ secretions from one site within the gastro-intestinal tract to other sites within the gastro-intestinal tract, to these low-profile implants.


According to various embodiments, the present invention is a method for creating a reversible treatment for metabolic disorders such as diabetes and obesity and gastro-esophageal reflux disease (GERD) consisting of (a) placing low-profile implants that can be affixed within the stomach, the esophagus, the intestine or at internal junctions of these organs or around these organs and (b) placing other gastro-intestinal implants that selectively restrict passage of food and organ secretions from one site within the gastro-intestinal tract to other sites within the gastro-intestinal tract, to these low-profile implants and not to the tissue so that the procedure can be reversed easily.


According to various embodiments, the present invention is a modular gastrointestinal implant system for treating metabolic disorders such as diabetes and obesity by creating partial internal bypasses of food and organ secretions within the gastro-intestinal tract. The system includes an anchoring element configured for engaging an esophagus, the anchoring element having a docking feature; a first gastrointestinal implant having a coupling feature for engaging and coupling with the docking feature of the anchoring element and sized and shaped to extend from the esophagus to the duodenal bulb; wherein the docking feature and coupling feature are configured such that the first implant may releasably couple with the anchoring element to facilitate removal of the tubular implant; and a second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum; wherein the first and second implants are adapted to partially overlap within the duodenal bulb.


According to some embodiments, the present invention is a modular gastrointestinal implant system for treating metabolic disorders such as diabetes and obesity by creating partial internal bypasses of food and organ secretions within the gastro-intestinal tract. The system includes a first anchoring element configured for engaging an esophagus, the first anchoring element having a docking feature; a second anchoring element configured for engaging a duodenum; a first gastrointestinal implant having a proximal end including a coupling feature for engaging the docking feature of the first anchoring element and a distal end adapted to couple with the second anchoring element; wherein the docking feature and coupling feature are configured such that the first implant may releasably couple with the anchoring element to facilitate removal of the tubular implant; and a second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum, the second implant adapted to couple with the second anchoring element; wherein the first and second implants are adapted to partially overlap within the second anchoring element.


According to various embodiments, the present invention is a method of treating metabolic conditions such as diabetes and obesity, which method includes securing a first anchoring element to the esophagus, the first anchoring element having a docking feature; securing a second anchoring element to the duodenum; implanting a first gastrointestinal implant having a proximal end including a coupling feature for engaging the docking feature of the first anchoring element and a distal portion adapted to couple with the second anchoring element; releasably coupling the coupling feature of the first gastrointestinal implant with the docking feature of the first anchoring element and coupling the distal portion with the second anchoring element; implanting a second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum, the second implant adapted to couple with the second anchoring element; coupling the second implant to the second anchoring element, such that the first and second implants partially overlap within the second anchoring element.


According to various embodiments, the present invention is a gastrointestinal implant system for treating metabolic disorders such as diabetes and obesity by creating partial internal bypasses of food and organ secretions within the gastro-intestinal tract, which system includes a first gastrointestinal implant having a feature for engaging and coupling with the docking feature of the anchoring element and sized and shaped to extend from the esophagus to the duodenal bulb; and a second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum; wherein the first and second implants are adapted to partially overlap within the duodenal bulb.


Furthermore, other documents that contemplate gastric and intestinal bypass using sleeve elements (e.g., WO/2007/136468) have a significant drawback. The sleeve element between the esophagus and the intestine passing through the stomach has no propulsion means to push food forward. Hence, if all the food from the esophagus (which is at this stage in semi-solid form) were to enter this section of the sleeve, it is possible there will be a backup of food causing dysphagia-like symptoms in the patient. Embodiments of the present invention describe partial bypass elements where only part of the food bypasses the stomach, such that if there is resistance to the passage of the food through the sleeve element, the food has an alternative pathway to move forward hence eliminating the chances of dysphagia.


While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1-4 are sectional views of a portion of the digestive tract in the body showing partial bypass systems having an external band implanted around the outside diameter of the esophagus and a first tubular implant (sleeve) implanted inside the esophagus and anchored to the external band. A first tubular implant extends through the stomach into the duodenal bulb and a second implant (sleeve) is implanted in the stomach antrum and extends into and/or through the duodenum.



FIG. 5 shows an exemplary endoscope used for diagnostic and therapeutic procedures in the gastro intestinal (GI) tract.



FIG. 6 is a sectional view of a portion of the digestive tract in the body, with an endoscope passing through the esophagus into the stomach, and the end of the scope positioned to allow viewing of the pylorus.



FIG. 7 is a schematic view showing a trocar and cannula operable to access the implant location of the duodenal bulb using laparoscopic techniques.



FIG. 8 is a sectional view of a portion of the digestive tract in the body. An implant is implanted in the duodenal bulb. The implant has two interior lumens as in section A-A or the alternative section A-A that allow two tubular implants to be sleeved adjacent to each other (i.e., overlapping).



FIG. 9 is a sectional view of a portion of the digestive tract in the body. A first implant is implanted in the duodenal bulb and a second implant is implanted in the esophagus. The implants have two interior lumens as in section A-A or the alternative section A-A that allow two tubular implants to be sleeved adjacent to each other (i.e., overlapping).



FIGS. 10 and 11 are sectional views of a portion of the digestive tract in the body. An external anchor is positioned around the outside diameter of the esophagus and a bifurcation implant is implanted into the duodenal bulb. A first tubular implant (sleeve) is implanted in the esophagus and is anchored to the external anchor at a proximal portion and to the implant at a distal portion. A second sleeve is implanted in the stomach antrum extending into and/or through the duodenum.



FIGS. 12 and 13 are sectional views of a portion of the digestive tract in the body. An external anchor is positioned around the outside of the esophagus and a first tubular implant (sleeve) is implanted in the esophagus and anchored to the external anchor. The first tubular implant extends through the duodenum to the ligament of Treitz. A second sleeve is anchored to the external anchor and extends into and/or through the stomach.



FIGS. 14-16 are sectional views of a portion of the digestive tract in the body. An external anchor is implanted around the outside of the esophagus and a first tubular implant (sleeve) is implanted in the esophagus and anchored to the external anchor. The first tubular implant extends into the duodenum to duodenal bulb. A second sleeve is implanted from the esophagus into the stomach. A third sleeve is implanted from the pylorus or stomach antrum into or through the duodenum.



FIGS. 17-18 are sectional views of a portion of the digestive tract in the body. An external anchor is positioned around the outside of the esophagus. A first tubular implant (sleeve) is implanted inside the esophagus and anchored to the external anchor and extends from the esophagus into the duodenum to the duodenal bulb. The first tubular implant has a valve (section C-C) opening that (like stoma) allows some portion of the food entering the esophagus to enter the upper portion of the stomach. A second sleeve is implanted from the stomach antrum into or through the duodenum.



FIG. 19 is a sectional view of a portion of the digestive tract in the body. An external anchor is positioned around the outside of the esophagus. A bifurcated tubular implant (sleeve) is implanted on the inside of the esophagus and is anchored to the external anchor. A first branch of the bifurcated implant extends to an implant positioned in the duodenal bulb and a second branch extends into the stomach. A second tubular implant extends from the bifurcated tubular implant into the duodenum.



FIG. 20 is a schematic view of a delivery device for implanting an internal implant.





While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.


DETAILED DESCRIPTION


FIGS. 1 and 2 are sectional views of a portion of the digestive tract in a human body. As a person ingests food, the food enters the mouth 100, is chewed, and then proceeds down the esophagus 101 to the lower esophageal sphincter at the gastro-esophageal junction 102 and into the stomach 103. The food mixes with enzymes in the mouth 100 and in the stomach 103. The stomach 103 converts the food to a semi-fluid substance called chyme. The chyme enters the pyloric antrum 104 and exits the stomach 103 through the pylorus 106 and pyloric orifice 105. The small intestine is about 21 feet long in adults and is comprised of three sections: the duodenum 112, the jejunum 113, and the ileum (not shown). The duodenum 112 is the first portion of the small intestine and is typically 10-12 inches long. The duodenum 112 is comprised of four sections: the superior, descending, horizontal and ascending sections. The duodenum 112 ends at the ligament of Treitz 109. The papilla of Vater 108 is the duct that delivers bile and pancreatic enzymes to the duodenum 112. The duodenal bulb 107 is the portion of the duodenum which is closest to the stomach 103.


As shown, an external anchoring element or band 110 is secured or positioned around the outside of the esophagus and a first gastrointestinal or tubular implant 111 (e.g., sleeve) is implanted inside of the esophagus and anchored magnetically through the esophageal tissue to the external band 110. As shown in FIG. 1, magnets 135 on the anchoring element 110 and magnets 136 on the tubular implant 111 magnetically interact with (e.g., attraction, repulsion, or levitation) each other to anchor or secure the tubular implant 111 to the external band 110 in a removable or reversible configuration. The magnets 135 on the external anchoring element or band 110, which can be located on the inside surface, outside surface, or embedded in the middle of the band, serve as a coupling or docking feature. The magnets 136 on the tubular implant 111, which magnetically interact with the magnets 135 on the anchoring element, serve as a coupling feature for the implant 111. Suitable exemplary materials for the magnets include neodymium-iron-boron [Nd—Fe—B], samarium-cobalt [Sm—Co], alnico, and hard ferrite [ceramic]. The magnets may be plated with gold or platinum or other material to make them radio-opaque or to improve the corrosion resistance. The magnets may be encapsulated within a metal casing such as titanium or stainless steel to improve the corrosion resistance and the biocompatibility. According to various embodiments, the external band 110 is made from one or more elastomers (e.g., silicon, polyurethane, and ePTFE), metals, or fabrics (e.g., Dacron or a combination of polymers and textile materials).


As shown, the gastrointestinal implant 111 extends into the duodenum 112 to the duodenal bulb 107. According to some embodiments, the sleeve 111 or the anchor mechanism 110 may form a restrictive stoma 262 in the esophagus (see FIGS. 1 and 2), for example, by reducing or restricting the internal diameter of the esophagus. According to other embodiments, as shown for example in FIGS. 3 and 4, a stoma is not formed. A second sleeve 300 or 301 is implanted from the stomach antrum 104 (or from the duodenal bulb 107) to the mid-portion of the duodenum (see, e.g. FIG. 1) or to the ligament of Treitz (see, e.g., FIG. 2). According to some embodiments, the two sleeves each form a D-shaped transverse section in the overlap section (e.g., the region in or near the duodenal bulb 107), such that when combined they together form a generally circular overall transverse cross-section (see, e.g., section A-A in FIGS. 1 and 2). The first sleeve 111 (extending between the esophagus 102 and the duodenal bulb 107) serves to bypass the stomach 103. The second sleeve 300 (or sleeve 301) allows the stomach secretions to bypass a portion (or all) of the duodenum 112. According to some embodiments, at least one of the first sleeve 111 and the second sleeve 300 are formed or shaped such that the portion of the sleeve located in the duodenal bulb has and generally holds the D-shape cross section (as shown in section A-A). In other embodiments, these portions of the first sleeve and/or second sleeve 300 are not preformed or shaped, but instead are made from a material having sufficient compliance to conform to the duodenal bulb, in such a way as to have a substantially D-shape cross section.


According to other embodiments, the anchoring mechanism 110 may be formed from other structures. Exemplary structures (shown in FIG. 1) include a stent 500 and/or interlocking mechanical rings 501. The stent 500 can be a self expanding type or a balloon expandable type. As shown, the rings 501 are configured such that an outer ring 141 positioned around an outer surface of the esophagus is sized and shaped to interlock with an inner ring 143a or 143b positioned around an inner surface of the esophagus. According to some embodiments, the anchoring mechanism 110 is integrally formed with the sleeve 111, and, in other embodiments, the anchoring mechanism is structurally separate from and adapted for coupling with the sleeve 111. According to other embodiments, any of the internal anchoring structures disclosed in co-pending, commonly assigned U.S. patent application Ser. No. 12/752,697 (incorporated herein by reference) may be used as the anchoring mechanism 110. According to still other embodiments, any of the external anchoring structures disclosed in co-pending, commonly assigned U.S. patent application Ser. No. 12/833,605 (incorporated herein by reference) may be used as the anchoring mechanism 110. Likewise, the implants or sleeves 111 and 300 may be formed in any configuration or from any material disclosed in either of U.S. patent application Ser. Nos. 12/752,697 or 12/833,605. Likewise the implants or sleeves may be couples or anchored to the anchoring mechanism using any arrangement disclosed in either of U.S. patent application Ser. Nos. 12/752,697 or 12/833,605.



FIG. 3 is an alternative embodiment of FIG. 1 where the tubular implant does not cause or form a stoma in the esophagus. FIG. 4 is an alternative embodiment of FIG. 2 where the tubular implant does not cause or form a stoma in the esophagus.



FIG. 5 shows an endoscope 114. Endoscopes 114 are used for diagnostic and therapeutic procedures in the gastrointestinal (GI) tract. The typical endoscope 114 is steerable by turning two rotary dials 115 to cause deflection of the working end 116 of the endoscope. The working end (or distal end) of the endoscope 116 typically contains two fiber bundles for lighting 117, a fiber bundle for imaging 118 (viewing) and a working channel 119. The working channel 119 can also be accessed on the proximal end of the endoscope. The light fiber bundles and the image fiber bundles are plugged into a console at the plug in connector 120. The typical endoscope has a working channel in the 2.6 mm to 3.2 mm diameter range. The outside diameters of the endoscopes are typically in the 8 mm to 12 mm diameter range, depending on whether the endoscope is for diagnostic or therapeutic purposes.



FIG. 6 shows a sectional view of a portion of the digestive tract in a human body. As shown in FIG. 6, an endoscope 114 has been inserted through: the mouth 100, esophagus 101, stomach 103 and pyloric antrum to allow visualization of the pylorus 106.



FIG. 7 shows a sectional view of a portion of the digestive tract in the body with a trocar 260 and cannula 261 inserted to access the implant location of the duodenal bulb, gastroesophageal junction, or other suitable location using laparoscopic techniques. An alternative access route is to use natural orifice surgery (e.g., access via the esophagus, stomach, belly button or vagina).



FIG. 8 shows a sectional view of a portion of the digestive tract in the body. As shown, a bifurcated anchor or implant 302 is implanted in the duodenal bulb 107 or pylorus 106. The implant has two interior lumens or anchoring structures 307, 309, as shown in section A-A or the alternative section A-A, that may couple with or otherwise allow two tubular implants to be sleeved adjacent to each other (i.e., overlapping). According to other embodiments, the implant 302 is structured to have D-shaped transverse sections, as shown above for example in section A-A in FIGS. 1 and 2. According to various embodiments, the implant 302 is configured to couple or anchor to the duodenal bulb 107 (or pylorus 106) and serves as an anchoring location for an end of the tubular implants or sleeves. According to various embodiments, the anchoring mechanism 110 includes structures to urge or otherwise cause the overlapping portions of the first sleeve 111 and the second sleeve 300 to form a specified shape, such as the D-shape described above and shown, for example, in section A-A of FIG. 1.


In the embodiments such as that shown in section A-A, the implant 302 further includes an area 311 which is located inside the implant 302 and outside the lumens 307, 309. The anchor or implant 302, according to various embodiments, includes a transition or seal feature covering the area 311 (shown for example in FIG. 8 below section A-A). This transition of seal feature may be shaped and configured to block or cover the area 311 (either partially or entirely), such that materials exiting the stomach cannot substantially bypass the sleeves coupled to either of the lumens 307, 309. In various embodiments, this seal feature may be a sleeve, film or other structure made from, for example, a urethane or Goretex material. In some embodiments, the area 311 is covered with a structure made from one or more elastomers (e.g., silicon, polyurethane, and ePTFE), metals, or fabrics (e.g., Dacron or a combination of polymers and textile materials).



FIG. 9 shows a sectional view of a portion of the digestive tract in the body. As shown, a bifurcated implant 302 is implanted into the duodenal bulb 107 (or pylorus 106). A second bifurcation implant 303 is implanted in the esophagus 102. According to various embodiments, the second implant 303 is formed of any of the configurations described above with respect to the bifurcated implant 302.



FIG. 10 is a sectional view of a portion of the digestive tract in a human body. As shown, a tubular implant 111 (sleeve) is implanted inside the esophagus (e.g., on the inside surface) and anchored mechanically or magnetically (as further described above) through the esophageal tissue to the external band 110 which is secured around the outside of the esophagus. As shown, the tubular implant 111 extends into the duodenum 112 to the duodenal bulb 107. The sleeve in the esophagus may form a restrictive stoma 262 in the esophagus. A second sleeve 300 is implanted from the stomach antrum 104 to the mid-portion of the duodenum.


As further shown in FIGS. 10 and 11, the two sleeves are inserted into a bifurcated implant 302 to anchor the sleeves and form the transition shape. According to some embodiments, the two sleeves each form a circular shape individually in the overlapping section. The two round sections of the implant form a combined round outer diameter (see, e.g., section A-A in FIG. 10). According to other embodiments, the overlapping ends of the sleeves 111, 300 (i.e., the distal end of the sleeve 111 and the proximal end of the sleeve 300) are formed with (or are otherwise capable of conforming to) a D-shaped section, such that collectively the ends form a generally circular transverse section shape. The sleeve between the esophagus 102 and the duodenal bulb 107 bypasses the stomach 103. The second sleeve is located from the distal stomach antrum 104 (or pylorus) to the mid-duodenum (see FIG. 10) or to the ligament of Treitz (see FIG. 11). The second sleeve 300 allows stomach secretions to bypass a portion of the duodenum 112.



FIGS. 12 and 13 show sectional views of a portion of the digestive tract in the body. As shown, an external band 110 is implanted around the outside of the esophagus. According to other embodiments, a bifurcated implant is implanted inside the esophagus. A tubular implant 111 (sleeve) is implanted on the inside surface of the esophagus and anchored magnetically or mechanically through the esophageal tissue to the external band 110. The tubular implant 111 extends into the duodenum (e.g., to the ligament of Treitz). As shown, the anchor or band around the esophagus forms a restrictive stoma 262 in the esophagus. A second sleeve 303 is implanted from the esophagus (again, anchored to the external band 110 or bifurcated implant) and extends into the upper portion of the stomach near the fundus 304 (see FIG. 12) or the lower portion of the stomach near the antrum 104 (see FIG. 13).


The two sleeves can each form a circular shape individually (see, e.g., section B-B and alternative section B-B) in the overlap section in the esophagus or alternatively the overlap portions of the sleeves can have or otherwise form D-shaped sections. The tubular element or sleeve 111 of the bypass system delivers food and secretions past the upper duodenum where as the rest of the food is allowed to flow into the upper duodenum where it will mix with the biliopancreatic secretions thus creating a partial duodenal bypass where controlled gastric emptying is still functional. Because of some level of biliopancreatic interaction with the food, this type of procedure is likely to result in the patient experiencing less complications such protein deficiency



FIGS. 14-16 show sectional views of a portion of the digestive tract in the body. As shown, an external anchor or band 110 is implanted around the outside diameter of the esophagus (or alternatively a bifurcated implant is implanted inside). A tubular implant 111 (sleeve) is implanted on the inside surface of the esophagus and anchored magnetically or mechanically through the esophageal tissue to the external band 110. The tubular implant 111 extends from the esophagus into the duodenal bulb where a distal portion of the implant 111 couples to bifurcated implant 302.


As shown, the anchor or band around the esophagus forms a restrictive stoma 262 in the esophagus. A second sleeve 303 is implanted from the esophagus (again, anchored to the external band 110 or bifurcated implant) and extends into the upper portion of the stomach near the fundus 304 (see FIG. 14) or the lower portion of the stomach near the antrum 104 (see FIGS. 15 and 16). As further described above, the two sleeves can each form a circular sectional shape (see section B-B in FIG. 14) in the overlap section in the esophagus or alternatively have or otherwise form D-shaped sections. A third sleeve 306 is implanted from the pylorus or stomach antrum and extends into the mid-duodenum (see, e.g., FIGS. 14 and 15) or to the ligament of Treitz (see, e.g., FIG. 16). The two sleeves overlapping in or near the duodenum (e.g., sleeve 111 and sleeve 306) can each form a circular shape (or alternatively D-shaped sections) as shown.


According to various embodiments, the gastrointestinal system includes two stents, a first stent in the esophagus and a second stent at the pyloric junction. The first stent couples to and secures a proximal portion of the implant 111 and a proximal portion of the second sleeve 303. The second stent couples to and secures a distal portion of the implant 111 and a proximal portion of the third sleeve 306.


As shown, the sleeve 111 includes a tubular element that bypasses a majority of the food ingested past the stomach emptying it in to the small intestine. The remainder of the food empties in to the stomach where it gets mixed with stomach enzymes and peptides such as Ghrelin released by the fundus of the stomach. The sleeve 306 at the pyloric junction redirects this mixture past the small intestine by means of the tubular element attached to it. Thus this system can mimic both the restrictive and malabsorptive features of a stomach reduction procedure as well as reduction of exposure of peptides such as Ghrelin to the upper duodenum.


An external anchor is positioned around the outside of the esophagus. A first tubular implant (sleeve) is implanted inside the esophagus and anchored to the external anchor and extends from the esophagus into the duodenum to the duodenal bulb. The first tubular implant has a valve (section C-C) opening that (like stoma) allows some portion of the food entering the esophagus to enter the upper portion of the stomach. A second sleeve is implanted from the stomach antrum into or through the duodenum.



FIGS. 17 and 18 show sectional views of a portion of the digestive tract in the body. As shown, an external anchor or band is implanted around the outside of the esophagus. According to alternative embodiments, a bifurcated implant is implanted inside. A tubular implant 111 (sleeve) is implanted on the inside surface of the esophagus and anchored magnetically or mechanically through the esophageal tissue to the external band 110. The tubular implant 111 extends into the duodenum to the duodenal bulb. The band around the esophagus forms a restrictive stoma 262 in the esophagus. A valve 307 is constructed into the wall of the sleeve 111. The valve acts as a stoma that can allow a portion of the food entering the sleeve 111 to exit the stoma opening into stomach. According to various embodiments, the valve 307 is any of an opening, a hole, a slit, or a mechanical valve mechanism. Exemplary structures for the valve 307 are shown in section C-C and alternative sections C-C in FIGS. 17 and 18. A second sleeve 306 is implanted from the pylorus or stomach antrum to the midpoint of the duodenum. As further described above, the two sleeves can each form a circular shape individually in the overlap section in the esophagus or alternatively “D” shaped sections (see, e.g., section A-A in FIGS. 17 and 18).



FIG. 19 shows a sectional view of a portion of the digestive tract in the body. As shown, an external band is implanted around the outside diameter of the esophagus (or alternatively a bifurcated implant is implanted inside). A bifurcated tubular implant 310 (sleeve) is implanted on the inside surface of the esophagus and anchored magnetically (or mechanically) through the esophageal tissue to the external band. A second tubular implant 311 extends from the bifurcated tubular implant 310 into the duodenum 112 to duodenal bulb 107. The band around the esophagus may form an optional restrictive stoma in the esophagus. A third sleeve 312 is implanted from the bifurcated tubular implant in the esophagus to the lower portion of the stomach near the stomach antrum or pylorus. A fourth sleeve 306 is implanted from the pylorus or stomach antrum to the middle or the end of the duodenum near the ligament of Treitz. As further described above, the two sleeves can each form a circular shape (or alternatively D shaped sections individually) in the overlap sections in the esophagus (or the duodenal bulb section). In some embodiments, the tubular implant 310 is formed in a branched (e.g., Y-shaped) configuration, having a proximal end adapted for coupling or anchoring in the esophagus and a distal portion including branches or limbs (e.g., sleeve 311 and sleeve 312). In other embodiments, the tubular implant 310 includes more than two branches (or limbs).


Various embodiments of the present invention shown and described above partial bypass elements where only part of the food bypasses the stomach (e.g., FIGS. 12-19). In these embodiments, there is an alternative flow path for food exiting the esophagus, such that if there is resistance to the passage of the food through the bypass sleeve element, the food has an alternative pathway to move forward. Such a configuration may help to reduce or eliminate dysphagia or dysphagia-like symptoms in a patient.



FIG. 20 shows a delivery catheter with an implant 110 loaded on to it for delivering a self-expanding internal tubular implant or stent. The catheter may be of an over-the-wire construction or a rapid exchange version. The delivery catheter is constructed with a smaller outside diameter to allow the catheter to be inserted through the working channel of the endoscope 114. The delivery catheter consists of an outer catheter 151 and an inner catheter 152. Attached to the inner catheter is a stent retainer 159. The purpose of the stent retainer 159 is to prevent the stent from releasing from the delivery catheter prematurely during deployment. The stent retainer is fastened to the inner catheter. The stent retainer 159 can be made from metal or plastic and can be made radio-opaque by making from it from a radio-opaque material such as tantalum. The stent retainer has a complementary shape that holds the tips on the stent and does not allow the stent to move distally or forward until the outer sheath 151 is fully retracted to the stent retainer 159. The catheter has a side port 156 which allows the space between the inner and outer sheaths to be flushed with saline. The outer sheath 151 and inner sheath 152 may be made from made from a simple single layer polymer extrusion such as from polyethylene or PTFE.


The outer sheath may also be constructed as follows. The sheath inner diameter surface is constructed of a thin wall PTFE liner 157. A layer of reinforcement 158 is placed over the PTFE liner. The reinforcement may be either a braid of wire or a coil of wire. The wire cross section can be either round or rectangular. The preferred material for the wire is a metal such as 316 or 304 stainless steel or Nitinol or other suitable material. The wire diameters are typically in the 0.0005 inch to 0.010 inch diameter range. The outer jacket material is preferably reflowed into the reinforcement layer by melting the material and flowing it into the spaces in between the braided wire or the coil wires. The outside diameter of this catheter will range typically from 1 mm to 4 mm. The catheter can be constructed to be an over the wire catheter or a rapid exchange catheter. For a rapid exchange design, the guide wire will enter the central lumen of the distal end of the catheter and exit at point 188. For an over-the-wire design, the guide wire will enter the central lumen of the distal end of the catheter and exit at point 189.


Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.

Claims
  • 1. A modular gastrointestinal implant system for treating metabolic disorders such as diabetes and obesity by creating partial internal bypasses of food and organ secretions within the gastro-intestinal tract, the system comprising: an anchoring element configured for engaging an esophagus, the anchoring element having a docking feature;a first gastrointestinal implant having a coupling feature for engaging and coupling with the docking feature of the anchoring element and sized and shaped to extend from the esophagus to the duodenal bulb;wherein the docking feature and coupling feature are configured such that the first gastrointestinal implant may releasably couple with the anchoring element to facilitate removal of the first gastrointestinal implant; anda second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum;wherein at least a portion of the first gastrointestinal implant extends laterally adjacent to at least a portion of the second gastrointestinal implant within the duodenal bulb.
  • 2. The system of claim 1 wherein the anchoring element is an expandable stent.
  • 3. The system of claim 1 wherein the anchoring element is a band and the docking feature includes one or more magnetic elements.
  • 4. The system of claim 1 wherein the docking feature consists of a hook or loop fastener element and the coupling feature consists of a complementary hook or loop fastener element that enables attachment of the first gastrointestinal implant to the anchoring element.
  • 5. The system of claim 1 wherein the docking feature includes a first mechanical element and the coupling feature includes a second mechanical element, and wherein the first and second mechanical elements are adapted to interlock.
  • 6. The system of claim 1 wherein the first and second gastrointestinal implants are thin tubular sleeves.
  • 7. The system of claim 1 wherein the first gastrointestinal implant is a Y-shaped sleeve having a first end with a single proximal branch and a second end including at least a first distal branch and a second distal branch.
  • 8. The system of claim 7 further comprising a second anchoring element adapted for securing at the gastro-intestinal junction and for coupling with both the first and the second gastrointestinal implants.
  • 9. The system of claim 8 wherein a proximal portion of the first gastrointestinal implant is connected to the anchoring element at the gastro-esophageal junction, the first distal branch is coupled to the second anchoring element, and the second distal branch is adapted to drain into the stomach.
  • 10. The modular system of claim 1 wherein one end of the first gastrointestinal implant is connected to the docking feature, which comprises multiple segments, at the gastrointestinal junction and another end of the first gastrointestinal implant or the second gastrointestinal implant extends farther down the duodenum.
  • 11. A modular gastrointestinal implant system for treating metabolic disorders such as diabetes and obesity by creating partial internal bypasses of food and organ secretions within the gastro-intestinal tract, the system comprising: a first anchoring element configured for engaging an esophagus, the first anchoring element having a docking feature;a second anchoring element configured for engaging a duodenum;a first gastrointestinal implant having a proximal end including a coupling feature for engaging the docking feature of the first anchoring element and a distal end adapted to couple with the second anchoring element;wherein the docking feature and coupling feature are configured such that the first implant may releasably couple with the first anchoring element to facilitate removal of the first gastrointestinal implant; anda second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum, the second gastrointestinal implant adapted to couple with the second anchoring element;wherein at least a portion of the first gastrointestinal implant extends laterally adjacent to at least a portion of the second gastrointestinal implant within the second anchoring element.
  • 12. The system of claim 11 wherein the first anchoring element is an expandable stent.
  • 13. The system of claim 11 wherein the first anchoring element is a band and the docking feature includes one or more magnetic elements.
  • 14. A method of treating metabolic conditions such as diabetes and obesity, the method comprising: securing a first anchoring element to the esophagus, the first anchoring element having a docking feature;securing a second anchoring element to the duodenum;implanting a first gastrointestinal implant having a proximal end including a coupling feature for engaging the docking feature of the first anchoring element and a distal portion adapted to couple with the second anchoring element;releasably coupling the coupling feature of the first gastrointestinal implant with the docking feature of the first anchoring element and coupling the distal portion with the second anchoring element;implanting a second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum, the second gastrointestinal implant adapted to couple with the second anchoring element;coupling the second gastrointestinal implant to the second anchoring element, such that at least a portion of the first gastrointestinal implant extends laterally adjacent to at least a portion of the second gastrointestinal implant within the second anchoring element.
  • 15. The method of claim 14 wherein the coupling feature and the docking feature are each magnetic structures adapted for magnetically coupling the first gastrointestinal implant to the first anchoring element.
  • 16. The method of claim 14 wherein the coupling feature and the docking feature are mechanical elements adapted to interlock without penetrating the gastrointestinal tract.
  • 17. A gastrointestinal implant system for treating metabolic disorders such as diabetes and obesity by creating partial internal bypasses of food and organ secretions within the gastro-intestinal tract, the system comprising: a first gastrointestinal implant having a feature for engaging and coupling within the esophagus, the first implant sized and shaped to extend from the esophagus to the duodenal bulb; anda second gastrointestinal implant adapted to extend from the stomach or the duodenal bulb into the duodenum;wherein at least a portion of the first gastrointestinal implant extends laterally adjacent to at least a portion of the second gastrointestinal implant within the duodenal bulb.
  • 18. The system of claim 17 wherein the feature for engaging and coupling within the esophagus is an expandable stent.
  • 19. The system of claim 17 wherein the feature for engaging and coupling within the esophagus includes a band and a docking feature having one or more magnetic elements.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. §119(e) to U.S. provisional patent application 61/335,472, filed Jan. 7, 2010, entitled “Apparatus and Methods for Customized and Partial Intraluminal Bypass Procedures,” which is herein incorporated by reference in its entirety. This application is a continuation-in-part of each of the following applications: U.S. patent application Ser. No. 12/752,697, filed Apr. 1, 2010, which claims the benefit of U.S. provisional patent application 61/211,853, filed Apr. 3, 2009; and U.S. patent application Ser. No. 12/833,605, filed Jul. 9, 2010, which claims the benefit of U.S. provisional patent application 61/270,588, filed Jul. 10, 2009, the disclosures of which are each hereby incorporated by reference in their entirety.

US Referenced Citations (311)
Number Name Date Kind
4134405 Smit Jan 1979 A
4204530 Finney May 1980 A
4246893 Berson Jan 1981 A
4315509 Smit Feb 1982 A
4416267 Garren et al. Nov 1983 A
4501264 Rockey Feb 1985 A
4641653 Rockey Feb 1987 A
4716900 Ravo et al. Jan 1988 A
4719916 Ravo Jan 1988 A
4763653 Rockey Aug 1988 A
4899747 Garren et al. Feb 1990 A
4905693 Ravo Mar 1990 A
5234454 Bangs Aug 1993 A
5246456 Wilkinson Sep 1993 A
5306300 Berry Apr 1994 A
5322697 Meyer Jun 1994 A
5423872 Cigaina Jun 1995 A
5474563 Myler et al. Dec 1995 A
5749921 Lenker et al. May 1998 A
5753253 Meyer May 1998 A
5820584 Crabb Oct 1998 A
6017563 Knight et al. Jan 2000 A
6267988 Meyer Jul 2001 B1
6454699 Forsell Sep 2002 B1
6540789 Silverman et al. Apr 2003 B1
6558400 Deem et al. May 2003 B2
6675809 Stack et al. Jan 2004 B2
6740121 Geitz May 2004 B2
6755869 Geitz Jun 2004 B2
6802868 Silverman et al. Oct 2004 B2
6845776 Stack et al. Jan 2005 B2
6946002 Geitz Sep 2005 B2
6994095 Burnett Feb 2006 B2
7025791 Levine et al. Apr 2006 B2
7037343 Imran May 2006 B2
7037344 Kagan et al. May 2006 B2
7044979 Silverman et al. May 2006 B2
7090699 Geitz Aug 2006 B2
7111627 Stack et al. Sep 2006 B2
7121283 Stack et al. Oct 2006 B2
7122058 Levine et al. Oct 2006 B2
7146984 Stack et al. Dec 2006 B2
7152607 Stack et al. Dec 2006 B2
7160312 Saadat Jan 2007 B2
7163554 Williams et al. Jan 2007 B2
7175638 Gannoe et al. Feb 2007 B2
7175669 Geitz Feb 2007 B2
7211094 Gannoe et al. May 2007 B2
7211114 Bessler et al. May 2007 B2
7214233 Gannoe et al. May 2007 B2
7220237 Gannoe et al. May 2007 B2
7220284 Kagan et al. May 2007 B2
7223277 Delegge May 2007 B2
7229428 Gannoe et al. Jun 2007 B2
7261725 Binmoeller Aug 2007 B2
7267694 Levine et al. Sep 2007 B2
7288099 Deem et al. Oct 2007 B2
7288101 Deem et al. Oct 2007 B2
7291160 Delegge Nov 2007 B2
7306614 Weller et al. Dec 2007 B2
7314489 Mckenna et al. Jan 2008 B2
7316716 Egan Jan 2008 B2
7329285 Levine et al. Feb 2008 B2
7335210 Smit Feb 2008 B2
7347875 Levine et al. Mar 2008 B2
7354454 Stack et al. Apr 2008 B2
7364542 Jambor et al. Apr 2008 B2
7364591 Silverman et al. Apr 2008 B2
7367937 Jambor et al. May 2008 B2
7431725 Stack et al. Oct 2008 B2
7476256 Meade et al. Jan 2009 B2
7503922 Deem et al. Mar 2009 B2
7507218 Aliski et al. Mar 2009 B2
7510559 Deem et al. Mar 2009 B2
7513914 Schurr et al. Apr 2009 B2
7569056 Cragg et al. Aug 2009 B2
7601178 Imran et al. Oct 2009 B2
7608114 Levine et al. Oct 2009 B2
7608578 Miller et al. Oct 2009 B2
7618435 Opolski et al. Nov 2009 B2
7628821 Stack et al. Dec 2009 B2
7678068 Levine et al. Mar 2010 B2
7682330 Meade et al. Mar 2010 B2
7695446 Levine et al. Apr 2010 B2
7758535 Levine et al. Jul 2010 B2
7766861 Levine et al. Aug 2010 B2
7766973 Levine et al. Aug 2010 B2
7815589 Levine et al. Oct 2010 B2
7837643 Levine et al. Nov 2010 B2
7837669 Dann et al. Nov 2010 B2
7935073 Levine et al. May 2011 B2
7976488 Levine et al. Jul 2011 B2
7981163 Meade et al. Jul 2011 B2
8114045 Surti Feb 2012 B2
8211186 Belhe et al. Jul 2012 B2
8282598 Belhe et al. Oct 2012 B2
20020183768 Deem et al. Dec 2002 A1
20020188354 Peghini et al. Dec 2002 A1
20030040804 Stack et al. Feb 2003 A1
20030040808 Stack et al. Feb 2003 A1
20030060894 Dua et al. Mar 2003 A1
20030109892 Deem et al. Jun 2003 A1
20030109931 Geitz Jun 2003 A1
20030109935 Geitz Jun 2003 A1
20030120265 Deem et al. Jun 2003 A1
20030158601 Silverman et al. Aug 2003 A1
20030191476 Smit Oct 2003 A1
20030199989 Stack et al. Oct 2003 A1
20030199990 Stack et al. Oct 2003 A1
20030199991 Stack et al. Oct 2003 A1
20040019388 Starkebaum Jan 2004 A1
20040024386 Deem et al. Feb 2004 A1
20040039452 Bessler Feb 2004 A1
20040088022 Chen May 2004 A1
20040092892 Kagan et al. May 2004 A1
20040093091 Gannoe et al. May 2004 A1
20040107004 Levine et al. Jun 2004 A1
20040117031 Stack et al. Jun 2004 A1
20040122452 Deem et al. Jun 2004 A1
20040122453 Deem et al. Jun 2004 A1
20040122526 Imran Jun 2004 A1
20040133147 Woo Jul 2004 A1
20040138760 Schurr Jul 2004 A1
20040138761 Stack et al. Jul 2004 A1
20040143342 Stack et al. Jul 2004 A1
20040148034 Kagan et al. Jul 2004 A1
20040158331 Stack et al. Aug 2004 A1
20040172141 Stack et al. Sep 2004 A1
20040172142 Stack et al. Sep 2004 A1
20040172143 Geitz Sep 2004 A1
20040199262 Dua et al. Oct 2004 A1
20040204768 Geitz Oct 2004 A1
20040220682 Levine et al. Nov 2004 A1
20040249362 Levine et al. Dec 2004 A1
20050004681 Stack et al. Jan 2005 A1
20050022827 Woo et al. Feb 2005 A1
20050033331 Burnett et al. Feb 2005 A1
20050043817 McKenna et al. Feb 2005 A1
20050049718 Dann et al. Mar 2005 A1
20050055039 Burnett et al. Mar 2005 A1
20050070934 Tanaka et al. Mar 2005 A1
20050075622 Levine et al. Apr 2005 A1
20050080395 Levine et al. Apr 2005 A1
20050080431 Levine et al. Apr 2005 A1
20050080444 Kraemer et al. Apr 2005 A1
20050080480 Bolea et al. Apr 2005 A1
20050080491 Levine et al. Apr 2005 A1
20050085923 Levine et al. Apr 2005 A1
20050096673 Stack et al. May 2005 A1
20050096750 Kagan et al. May 2005 A1
20050125020 Meade et al. Jun 2005 A1
20050125075 Meade et al. Jun 2005 A1
20050149200 Silverman et al. Jul 2005 A1
20050177181 Kagan et al. Aug 2005 A1
20050183730 Byrum Aug 2005 A1
20050192614 Binmoeller Sep 2005 A1
20050197714 Sayet Sep 2005 A1
20050228413 Binmoeller et al. Oct 2005 A1
20050228504 Demarais Oct 2005 A1
20050240279 Kagan et al. Oct 2005 A1
20050246037 Starkebaum Nov 2005 A1
20050247320 Stack et al. Nov 2005 A1
20050250980 Swanstrom et al. Nov 2005 A1
20050251157 Saadat et al. Nov 2005 A1
20050251206 Maahs et al. Nov 2005 A1
20050256587 Egan Nov 2005 A1
20050267499 Stack et al. Dec 2005 A1
20050273060 Levy et al. Dec 2005 A1
20050277963 Fields Dec 2005 A1
20050283107 Kalanovic et al. Dec 2005 A1
20050288555 Binmoeller Dec 2005 A1
20060009858 Levine et al. Jan 2006 A1
20060020247 Kagan et al. Jan 2006 A1
20060020277 Gostout et al. Jan 2006 A1
20060030949 Geitz Feb 2006 A1
20060064120 Levine et al. Mar 2006 A1
20060155310 Binmoeller Jul 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060155375 Kagan et al. Jul 2006 A1
20060161139 Levine et al. Jul 2006 A1
20060161172 Levine et al. Jul 2006 A1
20060161187 Levine et al. Jul 2006 A1
20060161265 Levine et al. Jul 2006 A1
20060178691 Binmoeller Aug 2006 A1
20060206063 Kagan et al. Sep 2006 A1
20060206064 Kagan et al. Sep 2006 A1
20060249165 Silverman et al. Nov 2006 A1
20060258906 Binmoeller Nov 2006 A1
20060265082 Meade et al. Nov 2006 A1
20060282087 Binmoeller Dec 2006 A1
20060293742 Dann et al. Dec 2006 A1
20070004963 Benchetrit Jan 2007 A1
20070005147 Levine et al. Jan 2007 A1
20070010794 Dann et al. Jan 2007 A1
20070010864 Dann et al. Jan 2007 A1
20070010865 Dann et al. Jan 2007 A1
20070010866 Dann et al. Jan 2007 A1
20070021761 Phillips Jan 2007 A1
20070027548 Levine et al. Feb 2007 A1
20070032702 Ortiz Feb 2007 A1
20070032879 Levine et al. Feb 2007 A1
20070038308 Geitz Feb 2007 A1
20070060932 Stack et al. Mar 2007 A1
20070078302 Ortiz et al. Apr 2007 A1
20070083271 Levine et al. Apr 2007 A1
20070100367 Quijano et al. May 2007 A1
20070118158 Deem et al. May 2007 A1
20070118159 Deem et al. May 2007 A1
20070135825 Binmoeller Jun 2007 A1
20070167963 Deem et al. Jul 2007 A1
20070198074 Dann et al. Aug 2007 A1
20070203517 Williams et al. Aug 2007 A1
20070213740 Deem et al. Sep 2007 A1
20070213748 Deem et al. Sep 2007 A1
20070213751 Scirica et al. Sep 2007 A1
20070213837 Ferreri et al. Sep 2007 A1
20070219570 Deem et al. Sep 2007 A1
20070239284 Skerven et al. Oct 2007 A1
20070250083 Deem et al. Oct 2007 A1
20070250132 Burnett Oct 2007 A1
20070265709 Rajan et al. Nov 2007 A1
20070276432 Stack et al. Nov 2007 A1
20070282349 Deem et al. Dec 2007 A1
20070282418 Weitzner Dec 2007 A1
20070282452 Weitzner et al. Dec 2007 A1
20070282453 Weitzner et al. Dec 2007 A1
20070282454 Krueger et al. Dec 2007 A1
20070293885 Binmoeller Dec 2007 A1
20080033574 Bessler et al. Feb 2008 A1
20080045803 Williams et al. Feb 2008 A1
20080065122 Stack et al. Mar 2008 A1
20080065136 Young Mar 2008 A1
20080071383 Levine et al. Mar 2008 A1
20080086214 Hardin et al. Apr 2008 A1
20080092910 Brooks Apr 2008 A1
20080097466 Levine et al. Apr 2008 A1
20080103604 Levine et al. May 2008 A1
20080109086 Voegele et al. May 2008 A1
20080109087 Durgin May 2008 A1
20080140172 Carpenter et al. Jun 2008 A1
20080161935 Albrecht et al. Jul 2008 A1
20080167606 Dann et al. Jul 2008 A1
20080167610 Dann et al. Jul 2008 A1
20080167629 Dann et al. Jul 2008 A1
20080167724 Ruane et al. Jul 2008 A1
20080183238 Chen Jul 2008 A1
20080195225 Silverman et al. Aug 2008 A1
20080195226 Williams et al. Aug 2008 A1
20080208135 Annunziata Aug 2008 A1
20080208161 Kaji et al. Aug 2008 A1
20080208224 Surti et al. Aug 2008 A1
20080208239 Annunziata Aug 2008 A1
20080208355 Stack et al. Aug 2008 A1
20080208356 Stack et al. Aug 2008 A1
20080208357 Melanson et al. Aug 2008 A1
20080221597 Wallace et al. Sep 2008 A1
20080221702 Wallace et al. Sep 2008 A1
20080234834 Meade et al. Sep 2008 A1
20080243151 Binmoeller et al. Oct 2008 A1
20080249533 Godin Oct 2008 A1
20080249566 Harris et al. Oct 2008 A1
20080249635 Weitzner et al. Oct 2008 A1
20080255476 Boyajian et al. Oct 2008 A1
20080255587 Cully et al. Oct 2008 A1
20080255594 Cully et al. Oct 2008 A1
20080255678 Cully et al. Oct 2008 A1
20080262529 Jacques Oct 2008 A1
20080269715 Faller et al. Oct 2008 A1
20080269797 Stack et al. Oct 2008 A1
20080287969 Tsonton et al. Nov 2008 A1
20080312559 Santilli et al. Dec 2008 A1
20080319455 Harris et al. Dec 2008 A1
20090005637 Chin et al. Jan 2009 A1
20090012541 Dahl et al. Jan 2009 A1
20090012542 N'diaye et al. Jan 2009 A1
20090012544 Thompson et al. Jan 2009 A1
20090012553 Swain et al. Jan 2009 A1
20090076588 Weber Mar 2009 A1
20090093767 Kelleher Apr 2009 A1
20090093839 Kelleher Apr 2009 A1
20090118749 Shalon et al. May 2009 A1
20090125119 Obermiller et al. May 2009 A1
20090138094 Schurr May 2009 A1
20090149871 Kagan et al. Jun 2009 A9
20090164028 Chen Jun 2009 A1
20090177215 Stack et al. Jul 2009 A1
20090182355 Levine et al. Jul 2009 A1
20090187206 Binmoeller et al. Jul 2009 A1
20090198210 Burnett et al. Aug 2009 A1
20090216262 Burnett et al. Aug 2009 A1
20090240105 Smit et al. Sep 2009 A1
20090240340 Levine et al. Sep 2009 A1
20090248171 Levine et al. Oct 2009 A1
20090276055 Harris et al. Nov 2009 A1
20090281379 Binmoeller et al. Nov 2009 A1
20090299486 Shohat et al. Dec 2009 A1
20090299487 Stack et al. Dec 2009 A1
20090326433 Albrecht et al. Dec 2009 A1
20090326675 Albrecht et al. Dec 2009 A1
20100004755 Imran Jan 2010 A1
20100016988 Stack et al. Jan 2010 A1
20100030017 Baker et al. Feb 2010 A1
20100256775 Belhe et al. Oct 2010 A1
20100305590 Holmes et al. Dec 2010 A1
20110009690 Belhe et al. Jan 2011 A1
20120065571 Thompson et al. Mar 2012 A1
20120184893 Thompson et al. Jul 2012 A1
20120253259 Belhe et al. Oct 2012 A1
20120253260 Belhe et al. Oct 2012 A1
20120302936 Belhe et al. Nov 2012 A1
20130030351 Belhe et al. Jan 2013 A1
Foreign Referenced Citations (127)
Number Date Country
2006227471 Sep 2006 AU
1618411 May 2005 CN
0137878 Apr 1985 EP
1420730 May 2004 EP
1492477 Jan 2005 EP
1492478 Jan 2005 EP
1520528 Apr 2005 EP
1555970 Jul 2005 EP
1569582 Sep 2005 EP
1585458 Oct 2005 EP
1585460 Oct 2005 EP
1603488 Dec 2005 EP
1680054 Jul 2006 EP
1708641 Oct 2006 EP
1708655 Oct 2006 EP
1709508 Oct 2006 EP
1749482 Feb 2007 EP
1750595 Feb 2007 EP
1768618 Apr 2007 EP
1778069 May 2007 EP
1786310 May 2007 EP
1799145 Jun 2007 EP
1817072 Aug 2007 EP
1832250 Sep 2007 EP
1850811 Nov 2007 EP
1850812 Nov 2007 EP
1881781 Jan 2008 EP
1883370 Feb 2008 EP
1887995 Feb 2008 EP
1895887 Mar 2008 EP
1933721 Jun 2008 EP
1937164 Jul 2008 EP
1992314 Nov 2008 EP
1416861 Dec 2008 EP
1749480 Dec 2008 EP
2010270 Jan 2009 EP
1610720 Feb 2009 EP
2023828 Feb 2009 EP
2026713 Feb 2009 EP
2061397 May 2009 EP
2066243 Jun 2009 EP
2068719 Jun 2009 EP
2080242 Jul 2009 EP
1610719 Jan 2010 EP
WO 9849943 Nov 1998 WO
WO 02096327 Dec 2002 WO
WO 03017882 Mar 2003 WO
WO 03086246 Oct 2003 WO
WO 03086247 Oct 2003 WO
WO 03094785 Nov 2003 WO
WO 2004011085 Feb 2004 WO
WO 2004017863 Mar 2004 WO
WO 2004041133 May 2004 WO
WO 2004049982 Jun 2004 WO
WO 2004064680 Aug 2004 WO
WO 2004064685 Aug 2004 WO
WO 2004087014 Oct 2004 WO
WO 2004087233 Oct 2004 WO
WO 2005037152 Apr 2005 WO
WO 2005058415 Jun 2005 WO
WO 2005060869 Jul 2005 WO
WO 2005060882 Jul 2005 WO
WO 2005065412 Jul 2005 WO
WO 2005097012 Oct 2005 WO
WO 2005099591 Oct 2005 WO
WO 2005110244 Nov 2005 WO
WO 2005110280 Nov 2005 WO
WO 2005112822 Dec 2005 WO
WO 2005120363 Dec 2005 WO
WO 2006014496 Feb 2006 WO
WO 2006016894 Feb 2006 WO
WO 2006020370 Feb 2006 WO
WO 2006028898 Mar 2006 WO
WO 2006034062 Mar 2006 WO
WO 2006060049 Jun 2006 WO
WO 2006062996 Jun 2006 WO
WO 2006078781 Jul 2006 WO
WO 2006078927 Jul 2006 WO
WO 2006102012 Sep 2006 WO
WO2006102240 Sep 2006 WO
WO 2006124880 Nov 2006 WO
WO 2006127593 Nov 2006 WO
WO 2006133311 Dec 2006 WO
2007019117 Feb 2007 WO
WO 2007030829 Mar 2007 WO
WO 2007038715 Apr 2007 WO
WO 2007041598 Apr 2007 WO
WO 2007075396 Jul 2007 WO
WO 2007092390 Aug 2007 WO
WO 2007107990 Sep 2007 WO
WO 2007127209 Nov 2007 WO
WO 2007136468 Nov 2007 WO
WO 2007139920 Dec 2007 WO
WO 2007142829 Dec 2007 WO
WO 2007142832 Dec 2007 WO
WO 2007142833 Dec 2007 WO
WO 2007142834 Dec 2007 WO
WO 2007145684 Dec 2007 WO
WO 2008005510 Jan 2008 WO
WO 2008030403 Mar 2008 WO
WO 2008033409 Mar 2008 WO
WO 2008033474 Mar 2008 WO
WO 2008039800 Apr 2008 WO
WO 2008101048 Aug 2008 WO
WO 2008106041 Sep 2008 WO
WO 2008106279 Sep 2008 WO
WO 2008112942 Sep 2008 WO
WO 2008127552 Oct 2008 WO
WO 2008141288 Nov 2008 WO
WO 2008148047 Dec 2008 WO
WO 2008150905 Dec 2008 WO
WO 2008154450 Dec 2008 WO
WO 2008154594 Dec 2008 WO
WO 2009011881 Jan 2009 WO
WO 2009011882 Jan 2009 WO
WO 2009012335 Jan 2009 WO
WO 2009036244 Mar 2009 WO
WO 2009046126 Apr 2009 WO
WO 2009082710 Jul 2009 WO
WO 2009085107 Jul 2009 WO
WO 2009086549 Jul 2009 WO
WO 2009097582 Aug 2009 WO
WO 2009097585 Aug 2009 WO
WO2010115011 Oct 2010 WO
WO2011062882 May 2011 WO
WO 2011073970 Jun 2011 WO
WO2011099940 Aug 2011 WO
Non-Patent Literature Citations (16)
Entry
International Search Report and Written Opinion issued in PCT/US2010/029648, mailed Aug. 24, 2010.
Invitation to Pay Additional Fees issued in PCT/US2010/029648, mailed Jun. 1, 2010.
Vetter, Marion et al., “Narrative Review: Effect of bariatric Surgery on Type 2 Diabetes Mellitus”, Annals of Internal Medicine, Jan. 20, 2009, 150(2), pp. 94-104.
Buchwald, Henry et al., “Bariatric Surgery: A Systematic Review and Meta-Analysis”, JAMA, Oct. 13, 2004, 292(14), pp. 1724-1737.
Rubino, Francesco et al., “Potential of Surgery for Curing Type 2 Diabetes Mellitus”, Annals of Surgery, Nov. 2002, 236(5), 554-559.
Cummings, David E. et al., “Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery”, Surgery for Obesity and Related Diseases 3 2007, pp. 109-115.
Strader, April et al., “Weight Loss Through Ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats”, Am J Physiol Endocrinol Metab 288: E447-E453, 2005.
Troy, Stephanie et al., “Intestinal Gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice”, Cell metabolism 8, 201-211, Sep. 3, 2008.
Rodriguez-Grunert, Leonardo et al., “First Human Experience With endoscopically Delivered and retrieved duodenal-jejunal bypass sleeve”, Surgery for Obesity and Related diseases 4 (2008) 55-59.
Rubino, Francesco et al,, “Effect of Duodenal-Jejunal Exclusion in a Non-Obese Animal Model of Type 2 Diabetes”, Annals of Surgery, vol. 239, No. 1, Jan. 2004, pp. 1-11.
Rubino, Francesco et al., “The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the pathophysiology of Type 2 Diabetes”, Annals of Surgery, 244(5), Nov. 2006, pp. 741-749.
International Search Report and Written Opinion issued in PCT/US2010/041574, mailed Jan. 25, 2011.
International Search Report and Written Opinion issued in PCT/US2011/061193.
International Search Report and Written Opinion issued in PCT/US2011/020560, mailed Mar. 28, 2011, 10 pages.
International Search Report and Written Opinion issued in PCT/US2012/023048, mailed Jun. 22, 2012.
International Search Report and Written Opinion issued in PCT/US12/58202, mailed Jan. 23, 2013, 14 pages.
Related Publications (1)
Number Date Country
20110106273 A1 May 2011 US
Provisional Applications (3)
Number Date Country
61335472 Jan 2010 US
61211853 Apr 2009 US
61270588 Jul 2009 US
Continuation in Parts (2)
Number Date Country
Parent 12833605 Jul 2010 US
Child 12986268 US
Parent 12752697 Apr 2010 US
Child 12833605 US